<DOC>
	<DOCNO>NCT02348229</DOCNO>
	<brief_summary>The investigator design prospective randomize , control clinical trial recruit 149 consecutive advanced gastric cancer patient . Further divide ERAS group ( n=73 ) conventional pathway group ( n=76 ) . Surgical technique group laparoscopic-assisted gastrectomy D2 lymphadenectomy . Compared outcomes included clinical parameter serum indicator .</brief_summary>
	<brief_title>Effect Enhanced Recovery After Surgery ( ERAS ) C-reactive Visceral Proteins</brief_title>
	<detailed_description>Enhanced recovery surgery combine laparoscopic-assisted gastrectomy successfully carry study . Recovery parameter length time return normal diet , mean hospital stay ( ) record .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>1 . Age 1875 year old 2 . Diagnosis confirm endoscopic biopsy totalbody CT scan 3 . No history chronic renal disease , chronic liver disease , cardiopulmonary dysfunction , ASA score≦3 4 . No neoadjuvant chemotherapy radiotherapy 5 . No digestive obstruction distant metastasis 1 . Conversion open gastrectomy 2 . A large amount bleed lead ( ＞500ml ) 3 . Patients withdraw consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Enhanced recovery surgery</keyword>
	<keyword>laparoscopic gastrectomy</keyword>
	<keyword>advanced gastric cancer</keyword>
	<keyword>C-reactive , visceral protein</keyword>
</DOC>